Introduction
Advances in precision medicine have transformed the treatment of non-small cell lung cancer (NSCLC), allowing therapies to target specific genetic mutations that drive tumor growth. For adults whose tumors carry certain epidermal growth factor receptor (EGFR) mutations, targeted medications may improve outcomes compared with older treatment approaches.
Lazcluze is an oral targeted therapy approved for use in combination with Rybrevant for adults with locally advanced or metastatic EGFR-mutated NSCLC. Together, these medications target complementary pathways involved in tumor growth, helping delay disease progression in eligible patients.
Because targeted cancer therapies are specialty medications, treatment costs can be substantial. Many patients search for a Lazcluze patient assistance program to help make therapy more affordable.
Prescription assistance programs through Prescription Hope may help eligible individuals access manufacturer-sponsored programs that reduce out-of-pocket medication costs.
What Is the Lazcluze Patient Assistance Program?
Understanding Lazcluze Prescription Assistance
Patients looking for affordable Lazcluze or help paying for Lazcluze understand the issues with rising retail costs of brand-name prescription medications.
To help solve this problem, manufacturers of medications like Lacluze and other brand-name meds often offer patient assistance programs. These provide qualified patients access to brand-name medications at affordable rates.
However, many of these programs have been known to include complex application processes that are difficult to navigate. Patients report feeling overwhelmed, with some even giving up on taking their medication due to costs.
Prescription Hope believes that no patient should go without their medication due to cost. To help, we’ve come up with a solution.
How Expert Advocates Help Make Lazcluze More Affordable
Personalized Medication Assistance
Prescription Hope’s team of patient advocates offers patient assistance application support and services. When a patient enrolls with us, our prescription assistance specialists manage the application process from start to finish.
This includes form completion, document and signature collection, coordination with healthcare providers and manufacturers, and much more.
Ongoing Patient Support
Not only does our team advocate on your behalf throughout the application process, but we continue to offer prescription refill assistance and medication access support.
We handle administrative tasks such as document updates, program monitoring, issue resolution, and yearly renewals.
Plus, our team even takes care of your refill scheduling, giving you peace of mind and the ability to focus on what matters most – quality of life.
Lazcluze Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Treatment Costs
Our specialty drug affordability program is included in a low service rate of $70.00 per month, per medication.
Lazcluze Patient Assistance Eligibility
General Eligibility Requirements
Eligibility requirements vary by assistance program but often consider factors such as:
- Prescription from a licensed healthcare provider
- Insurance status
- Household income
- U.S. residency or other program-specific requirements
Prescription Hope can help determine whether patients may qualify for available prescription assistance programs.
Simple Enrollment With Expert Support
Getting Started With Enrollment
The enrollment process to apply for Lazcluze assistance through Prescription Hope generally includes:
- Submit Information: It only takes a few minutes to complete our online enrollment form.
- Advocate Contact: Once we receive your form, a patient advocate will contact you within 1-2 business days.
- Document Collection: Following a quick prequalification, our team will collect needed documents
- Provider Coordination: We connect with your healthcare provider to secure vital signatures.
- Program Submission: Our team completes your application packet, submits it, and continues to follow up with the manufacturer.
- Medication Delivery: After approval, qualified patients typically receive their medication within 2 weeks. All medications ship directly from the manufacturer to your house or doctor’s office.
Understanding Lazcluze
How Lazcluze Works
Lazcluze works by blocking the activity of the epidermal growth factor receptor (EGFR), a protein that helps certain cancer cells grow and divide.
Some non-small cell lung cancers contain abnormal EGFR mutations that continuously signal cancer cells to grow. Lazcluze selectively and irreversibly inhibits mutant EGFR signaling, helping slow tumor growth and promote cancer cell death. When combined with Rybrevant (amivantamab-vmjw), the two medicines target complementary pathways involved in EGFR-mutated NSCLC, improving treatment effectiveness.
What Does Lazcluze Treat?
Lazcluze is FDA-approved in combination with Rybrevant® (amivantamab-vmjw) for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have:
- EGFR exon 19 deletion mutations, or
- EGFR exon 21 (L858R) substitution mutations,
as detected by an FDA-approved companion diagnostic test.
Lazcluze is intended for patients whose lung cancer has spread or cannot be removed surgically and whose tumors contain specific EGFR gene mutations.
Benefits of Treatment
For eligible patients with EGFR-mutated NSCLC, Lazcluze may:
- Slow cancer progression
- Extend progression-free survival
- Delay worsening of advanced lung cancer
- Target cancer cells with specific EGFR mutations
- Improve outcomes when used with Rybrevant compared with certain previous standard therapies
- Provide a personalized treatment option based on tumor genetic testing
Individual treatment outcomes vary depending on the patient’s overall health and disease characteristics.
Important Safety Information and Side Effects
Lazcluze does not carry an FDA Boxed Warning.
The most commonly reported side effects (primarily when used with Rybrevant) include:
- Rash
- Nail problems (paronychia)
- Muscle pain
- Swelling of the hands, feet, or ankles (edema)
- Mouth sores (stomatitis)
- Fatigue
- Dry skin
- Diarrhea
- COVID-19 infection
- Bleeding
- Decreased appetite
- Constipation
- Itching (pruritus)
- Infusion-related reactions (primarily attributable to Rybrevant)
Laboratory abnormalities may include:
- Low albumin
- Elevated liver enzymes
- Low sodium
- Low potassium
- Low hemoglobin
Patients should discuss the following important safety risks with their healthcare provider before beginning treatment:
- Venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism, which may be serious or fatal
- Interstitial lung disease (ILD) or pneumonitis, including potentially fatal cases
- Severe skin reactions, including rash
- Eye disorders, including keratitis and other vision problems
- Embryo-fetal toxicity (may cause harm to an unborn baby)
Patients receiving Lazcluze in combination with Rybrevant should also review the prescribing information for Rybrevant, which contains additional important safety warnings and precautions.
Lazcluze may cause fetal harm during pregnancy. Females of reproductive potential should use effective contraception during treatment and for 3 weeks after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for 3 weeks after the final dose.
Breastfeeding is not recommended during treatment and for 3 weeks after the final dose because of the potential for serious adverse reactions in a breastfed child.
Patients should inform their healthcare provider about all prescription medications, over-the-counter medicines, vitamins, and herbal supplements before beginning treatment. Particular caution is recommended with strong and moderate CYP3A inducers, which should generally be avoided because they may decrease lazertinib exposure and reduce treatment effectiveness.
Lazcluze is taken orally once daily and may be taken with or without food. Tablets should be swallowed whole and should not be crushed, split, or chewed. Lazcluze is always administered in combination with Rybrevant. When both medications are given on the same day, patients should take Lazcluze before the Rybrevant infusion. Treatment continues until disease progression or unacceptable toxicity and should be managed by oncology specialists experienced in treating lung cancer.
Access to Multiple Medications
Support Beyond Lazcluze
Prescription Hope works with patients seeking assistance for many brand-name specialty medications—not just Lazcluze. Individuals taking multiple prescription medications may be able to receive help accessing additional therapies through available patient assistance programs.
All of our services are included in our low service rate of $70.00 per month, per medication.
Why Choose Prescription Hope for Lazcluze Assistance
Patient-Focused Medication Support
Prescription Hope’s team of patient advocates has provided patient support and medication affordability for 20 years. Those looking for Lazcluze assistance through Prescription Hope can rest easy, knowing they’re getting two decades of expertise supporting them throughout the entire process.
Simplified Access to Prescription Medications
Prescription Hope helps simplify the application process by assisting eligible patients with enrollment into available prescription assistance programs, reducing administrative burden and improving access to needed medications.
All for $70.00 per month, per medication.
Ongoing Prescription Assistance
Prescription Hope continues supporting eligible patients throughout their participation in applicable assistance programs, helping them maintain access to prescribed medications as long as program requirements continue to be met.
Those looking for access to affordable Lacluze can enroll with Prescription Hope today and find out how they can save on their monthly medication costs.